Big data can be used cautiously to examine real world outcomes and to improve surveillance of drug safety. However, critics of the move say that big data are poor for identifying adverse events and the system may expose patients to overtreatment and associated harms. Read as Jeanne Lenzer investigates Big Data’s big bias.
